This exploratory study of cervical cancer revealed that patients with no tumor progression within 2 years after starting treatment had lower expression levels of PD-L1 and CD163 at the brachytherapy midpoint and that the expression rate of these molecules was related to the 2-year PFS. Here, CD163 is linked to cervical carcinoma.